Navigation Links
Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

SOUTH SAN FRANCISCO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George Scangos, Ph.D., the company's president and chief executive officer, will present at the 26th Annual JPMorgan Healthcare Conference at 7:30 a.m. PT / 10:30 p.m. ET on Thursday, January 10, 2008.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):